Friday , July 19 2019
Home / argentina / Female Viagra: approved in the United States an injectable drug for loss of sexual desire in women

Female Viagra: approved in the United States an injectable drug for loss of sexual desire in women



It is injectable and used 45 minutes before having sex, the drug from Palatin Technologies and Amag Pharmaceuticals, Vyleesi, will compete in a market that has seen thousands of previous attempts fail. Analysts say it is a drug that safely and effectively treats the loss of sexual desire in women and can reach annual sales of about one billion dollars.

Known chemically as bremelanotide, the drug activates pathways in the brain that are involved in sexual desire, and helps premenopausal women with acquired generalized hypoactive sexual desire order (HSDD) and will be available from September at selected pharmacies.

The drug will compete with Addyi by Sprout Pharmaceutical, the first pill approved for TDSH 2015. Addyi was approved under intense pressure from stakeholders despite an examination by researchers from the Food and Drug Administration (FDA) who considered it minimally effective and possibly uncertain.

The drug is given as an injection into the abdomen or thigh with an autoinjector at least 45 minutes before the expected sexual activity and the FDA recommends that patients not take more than one dose within 24 hours or more than eight doses per month.

According to analysts, Vyleesi, who does not limit alcohol consumption, has several advantages over Addyi as it does and is of daily consumption, including tolerable side effects and fast-acting nature.

However, the side effects reported during the clinical trials included mild to moderate nausea which lasted no more than two hours and occurred mainly in the first three doses. About 40% of patients in clinical trials experienced nausea and 13% had nausea that was large enough to require medication against them. The other major side effect was the darkening of the gums and the skin, especially on the face and sinuses, which was experienced by about 1% of the patients who received Vyleesi in clinical trials.


Source link